Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ORIC is a clinical stage oncology company with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ORIC, as reflected in its Form 8-K filings.
Investors can review current reports on Form 8-K in which ORIC discloses material events such as quarterly financial results, clinical program updates, and corporate presentations. For example, the company has filed 8-Ks to announce financial results for quarters ended June 30 and September 30, 2025, to furnish updated ORIC-944 corporate presentation slides, and to provide an enozertinib (ORIC-114) program update summarizing Phase 1b trial data. Certain 8-Ks also describe strategic pipeline prioritization measures, including workforce reductions and a focus on lead programs ORIC-944 and enozertinib.
ORIC’s filings include details on its status as an emerging growth company, the registration of its common stock on The Nasdaq Global Select Market, and exhibits such as press releases and investor presentations. These documents also contain cautionary notes regarding forward-looking statements and refer readers to risk factor discussions in periodic reports like Form 10-Q.
On Stock Titan, ORIC’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points of lengthy filings by highlighting items such as reported financial results, clinical milestones, strategic changes, and capital raising activities. Users can quickly see what each 8-K covers, identify attached exhibits such as presentations, and understand how new disclosures may relate to ORIC’s oncology pipeline and Nasdaq-listed equity.
In addition to 8-Ks, this page links to ORIC’s other SEC documents available on EDGAR, allowing investors to follow the company’s regulatory history, governance disclosures, and risk factor updates as its clinical programs advance.
Oric Pharmaceuticals, Inc. notice reports a proposed sale of 250,000 common shares through J.P. Morgan Securities LLC on 09/22/2025 with an aggregate market value of $2,625,000. The issuer has 97,122,987 shares outstanding, making the offered amount a small fraction of total shares. The filer states the 250,000 shares were acquired in an open market purchase on 05/11/2022 and were paid for in cash. The filing reports no securities sold in the past three months and includes the seller's certification regarding absence of undisclosed material adverse information.
Viking Global and affiliated entities report a passive 9.99% position in Oric Pharmaceuticals (ORIC). The Schedule 13G/A shows Viking Global Investors LP and related funds and entities collectively beneficially own 8,729,345 shares of Oric common stock on a fully reported basis, equal to 9.99% of 85,224,191 shares outstanding (May 29, 2025 basis). Holdings arise from directly owned common stock plus pre-funded warrants exercisable for additional shares, but exercise is limited by a contractual "Blocker" that caps beneficial ownership at 9.99% (adjustable up to 19.99% with notice). Ownership is held through VGOP and VGOD (detailed share and warrant counts provided), VGI provides managerial services and has shared voting/dispositive authority, and three named executives are disclosed as having shared authority. The filing certifies the stake is not intended to influence control.
ORIC Pharmaceuticals Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,162,637 shares of ORIC common stock, representing 8.4% of the outstanding class based on 85,225,191 shares. Nextech Crossover I GP S.a. r.l. is the general partner of Nextech Crossover I SCSp and Nextech principals Ian Charoub, Costas Constantinides and Rocco Sgobbo have voting and dispositive power over the shares. The filing states the position is not held to influence control of the issuer.
ORIC Pharmaceuticals reported continued clinical progress while strengthening its balance sheet. Cash, cash equivalents and investments totaled $327.7 million as of June 30, 2025, and management believes available resources are sufficient to fund operations into the second half of 2028. The company reported a net loss of $66.4 million for the six months ended June 30, 2025 and an accumulated deficit of $629.2 million.
Clinical updates include ORIC-944 combination data showing a 59% PSA50 response rate (47% confirmed) and 24% PSA90 (all confirmed) in mCRPC, and ORIC-114 advancing with provisional RP2D levels of 80 mg and 120 mg and reported intracranial activity. Financing activity included a $125.0 million private placement closed May 29, 2025, ATM proceeds of $8.9 million through June 30, 2025 and subsequent ATM net proceeds of approximately $108.7 million through August 12, 2025. On August 12, 2025, the company announced a strategic pipeline prioritization that will eliminate its discovery research group, reduce workforce by approximately 20% and incur an estimated one-time cost of $1.9 million.
ORIC Pharmaceuticals issued a press release reporting results for the quarter ended June 30, 2025 and announced a strategic pipeline prioritization to concentrate resources on its two lead clinical programs, ORIC-944 and ORIC-114. As part of the refocus, the company will eliminate its discovery research group, reducing headcount by approximately 20%.
The company expects a one-time charge of approximately $1.9 million, primarily for termination and healthcare-related benefits, with the workforce reduction substantially complete and the majority of related charges to be recognized in the third quarter of 2025. The company noted these estimates are subject to assumptions and may change.
Oric Pharmaceuticals CFO Dominic Piscitelli executed significant stock sales on June 23-24, 2025, through a pre-planned Rule 10b5-1 trading plan established on December 30, 2024. The transactions included:
- June 23: Sale of 584 shares at $10.00 and 450 shares at $10.01
- June 24: Sale of 32,466 shares at weighted average price of $10.5045 (range $10.34-$10.80)
Following these transactions, Piscitelli's direct ownership decreased from 101,233 to 68,317 shares, representing a roughly 32.5% reduction in his holdings. The sales were executed according to a predetermined trading plan, which helps avoid concerns about insider trading by establishing sale parameters in advance. The transactions demonstrate significant insider selling activity by a key executive officer.
ORIC Pharmaceuticals has filed a 424B3 prospectus for the resale of up to 19,230,845 shares of common stock by selling stockholders. This includes 14,130,313 outstanding shares and 5,100,532 shares issuable upon exercise of pre-funded warrants from a May 2025 private placement that raised approximately $125 million at $6.50 per share.
The company is advancing two key clinical-stage candidates:
- ORIC-944: A PRC2 inhibitor for prostate cancer, showing promising Phase 1b results. Currently in combination trials with apalutamide and darolutamide. Phase 3 trial planned for H1 2026.
- ORIC-114: A brain-penetrant EGFR/HER2 inhibitor for solid tumors, demonstrating both systemic and intracranial activity. Phase 1b trials ongoing with data updates expected in H2 2025 and Phase 3 trials planned for 2026.
As an emerging growth company, ORIC focuses on developing therapies targeting cancer resistance mechanisms in hormone-dependent cancers, precision oncology, and tumor dependencies.
Insider Trading Alert: Angie You, Director at Oric Pharmaceuticals (ORIC), has made significant stock purchases over two consecutive days in June 2025:
- June 20, 2025: Acquired 26,597 shares at weighted average price of $9.3871 per share
- June 23, 2025: Purchased additional 1,403 shares at $9.43 per share
Total position following these transactions: 28,000 shares held directly. The first purchase was executed across multiple price points ranging from $9.14 to $9.50. These direct market purchases by a director signal potential confidence in the company's prospects. The transactions were reported via Form 4 filing and executed through an attorney-in-fact, Christian Kuhlen.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
